Flip Biotechnologies, a developer of novel mRNA medicines and enabling applied sciences, immediately introduced an unique world licensing settlement with pharmaceutical producer HanAll Biopharma to develop groundbreaking medicines for the therapy of age-related eye and ear circumstances.
The settlement, doubtlessly exceeding $300 million in worth for the primary of a number of deliberate merchandise, considerably expands the connection between the businesses. HanAll initially invested in Flip Bio in 2022.
A New Frontier in Age-Associated Therapies
Merchandise ensuing from this collaboration will make the most of Flip Bio’s Epigenetic Reprogramming of Age (ERA™) know-how and its novel eTurna™ supply platform. These cutting-edge applied sciences goal to revive optimum gene expression, combatting the consequences of getting old on the mobile stage to deal with and doubtlessly treatment power circumstances.
“This partnership is a milestone for Flip Bio,” mentioned firm CEO Anja Krammer. “With HanAll’s assist, we’re accelerating the event of transformative therapies for eye and ear indications, which might profit sufferers around the globe. The potential impression on sufferers’ lives is gigantic, and that is just the start.”
HanAll has carefully monitored Flip Bio’s progress since its preliminary funding, recognizing the revolutionary potential of its epigenetic reprogramming know-how.
“Flip Bio’s modern strategy to epigenetic reprogramming aligns carefully with HanAll’s mission to discover modern medicines to broaden our therapeutic space,” mentioned Sean Jeong, M.D., MBA, CEO of HanAll Biopharma. “Collectively, we’re poised to pioneer new therapies that deal with essential unmet wants, significantly in aging-related illnesses.”
Increasing Horizons in Regenerative Drugs
The partnership expands Flip Bio’s growth, which had primarily centered on dermatology and immunology, to 2 different organs mostly affected by age-related circumstances. This implies Flip Bio is engaged on therapies to deal with and doubtlessly treatment most illnesses attributable to getting old.
“The facility of ERA™ know-how is that it may possibly rejuvenate cells in just about any organ within the physique,” mentioned Flip Bio Co-founder Vittorio Sebastiano, the corporate’s head of analysis. “This settlement allows us to speed up our growth on a number of fronts to reverse the injury attributable to getting old and enhance the standard of life for older sufferers.”
About Flip Biotechnologies
Flip Bio is a pre-clinical-stage firm centered on repairing tissue on the mobile stage and growing transformative drug supply techniques. The corporate’s proprietary mRNA-based ERA™ reprogramming know-how goals to revive optimum gene expression by combatting the consequences of getting old within the epigenome. This doubtlessly restores cells’ potential to forestall or deal with illness and heal or regenerate tissue and helps to combat incurable power illnesses. Its eTurna™ supply platform makes use of distinctive formulations to exactly ship cargo to particular organs, tissues, and cell sorts.
The corporate is finishing pre-clinical analysis on tailor-made therapies focusing on indications in dermatology and immunology, and growing therapies for ophthalmology, osteo-arthritis, and the muscular system. For extra data, see www.turn.bio.
About HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a worldwide biopharmaceutical firm with presence in Korea, the USA, Japan, and Indonesia with the mission of creating significant contributions to sufferers’ lives by introducing modern, impactful medicines to deal with extreme unmet medical wants. HanAll has been working a portfolio of pharmaceutical merchandise within the therapeutic areas of endocrine, circulatory, and urologic illnesses for over 50 years.
HanAll has additionally expanded its focus to immunology, oncology, neurology, and ophthalmology to find and develop modern medicines for sufferers with illnesses for which there are not any efficient therapies. Certainly one of its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Part 3 and Part 2 trials internationally for the therapy of autoimmune illnesses together with generalized myasthenia gravis (gMG), thyroid eye illness (TED), power inflammatory demyelinating polyneuropathy (CIDP), and Graves’ illness (GD). One other lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Part 3 scientific research within the US and can be being evaluated in China for the therapy of dry eye illness. HL161ANS, an anti-FcRn antibody focusing on a number of indications, and HL192 (ATH-399A), a Nurr1 activator presently focusing on Parkinson’s Illness, are additionally being evaluated in Part 1 scientific research (wholesome volunteers). For additional data, go to our website and join with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR ([email protected], [email protected]).
